Ethiotime1
Date: 23 February, 2022
Time: 13:00 to 19:30 CET
Download Agenda
The WHO R&D Blueprint organized a consultation to discuss emerging evidence towards the establishment of correlates of protection for COVID-19 vaccines. There is a global need to increase the supply of vaccines that likely meet the WHO TPP criteria for effectiveness against severe disease.
WHO is considering the development of a framework to help evaluate new vaccines, against currently circulating variants or for pan-sarbecovirus vaccines. This may also help inform researchers and developers decisions on how to generate additional data for the assessment of new vaccines.
The scientific elements of the proposed framework was presented and discussed during this meeting.
Watch the meeting recording here: https://who-e.zoom.us/rec/share/k-cF8FpBz5R337fyc96fJmdKNyyx4ygj0PwOj2IdErFoEjKWVHLm1frdvC9x_kxn.JN0pKx31MKZtWvDO
PRESENTATIONS
Objectives of the meeting
Antibody responses to natural infection and vaccines
Framework for the evaluation of new vaccines
Session 1: COMPOSITION AND IMMUNE RESPONSES OF VACCINES
Evolutionary biology of SARS-CoV-2 Variants
Overview of antigenic composition of current vaccines
CMI Epitopes – Virus and Vaccines: What do we need for protection?
Mucosal immunity: What do we need for protection?
Non-neutralizing humoral epitopes: What do we need for protection?
Session 2: WHAT DO VACCINE PLATFORMS TELL US ABOUT LIKELY IMMUNE RESPONSES?
Immune responses that confer protection against severe disease and variants, short- and long-term protection
Immune responses induced by different platforms
Importance of measuring SARS-CoV-2-specific CMI responses
Early innate immune responses to vaccinations as predictors or protection
Assays and Interpreting CMI responses
What does the data suggest regarding vaccine induced protection to omicron?
Session 3: WHAT COMPARATORS ARE LIKELY TO YIELD RELIABLE INSIGHT INTO VACCINE EFFECTIVENESS?
Current WHO Target Product Profile
Why selection of a comparator and assumptions on its efficacy are essential? Part 1
Why selection of a comparator and assumptions on its efficacy are essential? Part 2
Session 4: WHAT ADDITIONAL DATA DO WE NEED AND WHAT ARE THE STUDY DESIGNS?
Overview of seroprevalence against SARS-CoV-2 WHO
In-deployment studies
Other study designs to address durability of protection
Can human challenge studies provide critical information?
Safety data needed to inform decisions
Main conclusions and next steps
Watch the meeting recording here:
PRESENTATIONS
Objectives of the meeting
Antibody responses to natural infection and vaccines
Framework for the evaluation of new vaccines
Session 1: COMPOSITION AND IMMUNE RESPONSES OF VACCINES
Evolutionary biology of SARS-CoV-2 Variants
Overview of antigenic composition of current vaccines
CMI Epitopes – Virus and Vaccines: What do we need for protection?
Mucosal immunity: What do we need for protection?
Non-neutralizing humoral epitopes: What do we need for protection?
Session 2: WHAT DO VACCINE PLATFORMS TELL US ABOUT LIKELY IMMUNE RESPONSES?
Immune responses that confer protection against severe disease and variants, short- and long-term protection
Immune responses induced by different platforms
Importance of measuring SARS-CoV-2-specific CMI responses
Early innate immune responses to vaccinations as predictors or protection
Assays and Interpreting CMI responses
What does the data suggest regarding vaccine induced protection to omicron?
Session 3: WHAT COMPARATORS ARE LIKELY TO YIELD RELIABLE INSIGHT INTO VACCINE EFFECTIVENESS?
Current WHO Target Product Profile
Why selection of a comparator and assumptions on its efficacy are essential? Part 1
Why selection of a comparator and assumptions on its efficacy are essential? Part 2
Session 4: WHAT ADDITIONAL DATA DO WE NEED AND WHAT ARE THE STUDY DESIGNS?
Overview of seroprevalence against SARS-CoV-2 WHO In-deployment studies
Other study designs to address durability of protection
Can human challenge studies provide critical information?
Safety data needed to inform decisions
Main conclusions and next steps
Watch the meeting recording here:
“,”startDate”:”2022-02-23T12:00:00.0000000+00:00″,”endDate”:”2022-02-23T18:30:00.0000000+00:00″,”image”:”https://cdn.who.int/media/images/default-source/health-topics/who_vaccine-topic-12_banner.jpg?sfvrsn=5e95d538_17″,”url”:”https://www.who.int/news-room/events/detail/2022/02/23/default-calendar/developing-a-framework-for-evaluating-new-covid-19-vaccines”,”performer”:{“@type”:”Organization”,”name”:”World Health Organization: WHO”,”logo”:{“@type”:”ImageObject”,”url”:”https://www.who.int/Images/SchemaOrg/schemaOrgLogo.jpg”,”width”:250,”height”:60}},”@context”:”http://schema.org”,”@type”:”Event”};
Source
GIPHY App Key not set. Please check settings